Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01267149
Other study ID # PRV-2010
Secondary ID
Status Recruiting
Phase N/A
First received December 23, 2010
Last updated December 27, 2010
Start date August 2010

Study information

Verified date December 2010
Source Goldman, Butterwick, Fitzpatrick and Groff
Contact Karina Brazdys, RN
Phone 858-657-1002
Email kbrazdys@gbk.com
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

Statistical Hypotheses The Null Hypothesis: There is no difference in the reduction of lines in the treated areas as compared to baseline.

Alternative Hypothesis: There is a difference in the reduction of lines in the treated areas as compared to baseline.


Recruitment information / eligibility

Status Recruiting
Enrollment 13
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria:

- Females and males in good general health between 35 to 65 years of age.

- Must be willing to give and sign a HIPPA form, informed consent form and a photographic release form

- Patient is planning to undergo Prevelle Silk treatment

- A potential subject's must exhibit:

A. moderate to severe superficial, vertical perioral and horizontal canthus lines

- For FEMALE PATIENT OF CHILDBEARING POTENTIAL, must have had a regular menstrual cycle prior to study entry (a female is considered of childbearing potential unless she is postmenopausal, without a uterus and/or both ovaries, or has had a bilateral tubal ligation) and is willing to use an acceptable form of birth control during the entire course of the study [i.e., acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplanit®, Depo-Provena®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies of partner with a documented second acceptable method of birth control should the patient become sexually active]. All systemic birth control measures must be in consistent use at least 30 days prior to study participation

- Negative urine pregnancy test results at the time of study entry (if applicable)

- Must be willing to comply with study regimen and complete the entire course of the study.

Exclusion Criteria:

- A patient with any UNCONTROLLED systemic disease. A potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study

- A patient with a significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.

- A patient with a known hypersensitivity to any of the components of the study medications

- A patient who is actively smoking or plans to smoke at any time of the duration of this study

- A patient with an active skin condition/disease that might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, eczema, psoriasis, seborrheic dermatitis, herpes labialis)

- A patient planning any other cosmetic procedure to their facial area during the study period, other than the treatments that will be performed by the investigator

- A patient using any topical (prescription or over the counter) medicated creams, lotions, gels, balms, powders, etc. on the treatment areas during the study period

- A patient receiving any topical products containing alpha-hydroxy acids, salicylic acid, and vitamins C or D (includes derivatives thereof) on the perioral or lateral canthal areas within 7 days prior to or during the study period, other than the study products

- A patient receiving any investigational drug and/or has had a microdermabrasion (light or medium skin peel) treatment on their perioral or lateral canthal areas within 30 days prior to or during the study period

- A patient using any topical tretinoin product or derivative on their perioral or lateral canthal areas within 12 weeks prior to or during the study period

- A patient receiving a chemical peel, any systemic steroids, a non-ablative laser, light or radio frequency treatment and/or has had a Dermabrasion (deep skin peel) or ablative laser treatments on their perioral or lateral canthal areas must have discontinued the drug/treatment and/or had the procedure at least 6 months prior to entering the study

- A patient that has previously been treated with botulinum toxin in the perioral or lateral canthal areas within the past six months

- A patient that has previously been treated with dermal filler in the perioral or lateral canthal areas within the past year

- A patient that with a history of allergic reaction to a dermal filler or lidocaine

- A patient that with a history of a permanent filler to the perioral or lateral canthal areas

- A female patient who is pregnant, nursing an infant or planning a pregnancy during the study [throughout the course of the study, women of child-bearing potential must use reliable forms of contraception (i.e., oral contraceptive, intrauterine device, abstinence, or spermicides and condoms used in combination)]

- Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
United States Goldman, Butterwick, Fitzpatrick and Groff La Jolla California
United States The Maas Clinic San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
Goldman, Butterwick, Fitzpatrick and Groff Mentor Worldwide, LLC

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT01984619 - Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles N/A
Completed NCT01713985 - Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck N/A
Recruiting NCT01586819 - Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A Phase 3
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT02604641 - Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin N/A
Completed NCT01460927 - TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides N/A
Completed NCT01519934 - A Retrospective Study to Evaluate the Effectiveness of the Ulthera System N/A
Completed NCT03811756 - The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT04988412 - The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT02913547 - Silk'n HST for Wrinkle Reduction - Clinical Study Protocol N/A
Active, not recruiting NCT02019004 - A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles N/A
Completed NCT02340078 - A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection N/A
Completed NCT01283464 - Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Phase 2
Completed NCT01034956 - Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections N/A
Completed NCT02425943 - Sculptra Aesthetic Post-Approval Study Phase 4
Recruiting NCT05847530 - Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions N/A
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Completed NCT01859611 - TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides N/A
Completed NCT01297634 - Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle Phase 4
Completed NCT05011461 - The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles N/A